CollPlant Ltd - נכסים נקיים למניה בודדת CLGN

While the recombinant collagen platform generates stable revenue from implants, the bioengineering team is developing innovative 3D tissue printing. The calculated book value per share helps balance these directions, where the value of 2.05 serves as the current metric. The development strategy relies on diversifying the unique technology into aesthetics and regeneration, reducing the risks of dependence on a single product for CollPlant Biotechnologies (CLGN).

This indicator reflects the residual value of capital minus all liabilities, determining the intrinsic value of a single asset in the event of business liquidation. For CollPlant Biotechnologies (CLGN), which holds a unique patent for plant-based collagen, the book value per share chart demonstrates how effectively investments in regenerative technologies are capitalized into the company's actual net assets.